Oxford's Zostavax-to-Shingrix switch closes the healthy-vaccinee loophole, and opens another

The design's strength and its limit are the same fact: everyone in both arms had a needle in their arm. Matching people who received Zostavax in the six months before October 2017 against those who received Shingrix in the six months after ^[2] removes the objection that dogged earlier work, where vaccinated people were compared with unvaccinated people who tended to be less healthy and less well connected to care ^[11]. It also changes the question being answered. Zostavax is not a placebo, so the reported 9 per cent is the gap between two vaccines ^[5], not the benefit of being vaccinated. The Danish trial that Maxime Taquet points to randomises Shingrix against no shingles vaccine at all ^[14], so its first results will speak to a different contrast and cannot confirm this figure.

Then there is the arithmetic across the two write-ups. New Scientist gives 10.9 per cent of the Zostavax group and 9.6 per cent of the Shingrix group with heart failure, stroke or clogged heart arteries by 3.5 years ^[9]. That is 1.3 percentage points ^[1], a relative reduction near 12 per cent ^[2], one event avoided per 77 people vaccinated ^[3]. STAT reports the seven-year figures as 9 per cent relative and about one percentage point absolute ^[5][8], which is one per 100 ^[4]. The relative effect is therefore smaller at seven years than at 3.5 ^[5], matching the researchers' statement that the benefit waned over the second half of follow-up while still favouring Shingrix ^[10]. An effect that peaks early and erodes fits protection against acute events better than a durable change in vascular biology.

That matters because the mechanism is unsettled. Betty Raman of Oxford pointed to AS01, the immune-stimulating component of Shingrix, reprogramming monocytes to make fewer inflammatory cytokines ^[15][16]. John Tregoning at Imperial College London offered the plainer route: Shingrix prevents shingles better, and infection brings inflammation that stresses organs including the heart ^[17]. If the adjuvant is doing the work, the result travels to other AS01 products; if it is simply better shingles prevention, the cardiac gain tracks vaccine efficacy and stops there. The authors say they can only speculate ^[18].

The population claim rests on neither. Taquet's estimate of hundreds of thousands of cardiovascular cases delayed or prevented within a decade assumes everyone aged 50 and over in the US receives Shingrix ^[19]; about a third of eligible people currently do ^[20], so the projection is priced at roughly triple today's coverage ^[6]. Two caveats sit in the data itself. TriNetX draws on 60 health systems but excludes people with public insurance ^[4], which thins the Medicare-age population in a study restricted to people 60 and older ^[3]. And October 2017 was also when US eligibility dropped from 60 to 50 ^[21]; the cohort's age floor keeps most of that expansion outside the comparison, though the two publishers describe the enrolment windows differently enough (six months either side, versus April to September 2017 and then the following year) ^[2][22] that the boundaries are worth seeing in the paper.